SUNRESTPharmaceuticals
Sunrest Lifescience Ltd — Profit & Loss Statement
₹37.00
-15.03%
Sunrest Lifescience Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | -0.04 Cr | 58260.47 | — |
| Tax Rate For Calcs | 0.23 | 0.30 | 0.26 | 0.26 | — |
| Normalized EBITDA | 3.02 Cr | 0.91 Cr | 3.10 Cr | 1.11 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | -0.17 Cr | 0.02 Cr | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | -0.17 Cr | 0.02 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 2.01 Cr | 0.23 Cr | 2.04 Cr | 0.78 Cr | — |
| Reconciled Depreciation | 0.10 Cr | 0.10 Cr | 0.13 Cr | 0.06 Cr | — |
| Reconciled Cost Of Revenue | 20.08 Cr | 19.98 Cr | 14.88 Cr | 17.46 Cr | — |
| EBITDA | 3.02 Cr | 0.91 Cr | 2.93 Cr | 1.13 Cr | — |
| EBIT | 2.93 Cr | 0.81 Cr | 2.80 Cr | 1.07 Cr | — |
| Net Interest Income | -0.31 Cr | -0.22 Cr | -0.03 Cr | -0.02 Cr | — |
| Interest Expense | 0.31 Cr | 0.22 Cr | 0.06 Cr | 0.02 Cr | — |
| Normalized Income | 2.01 Cr | 0.23 Cr | 2.17 Cr | 0.76 Cr | — |
| Net Income From Continuing And Discontinued Operation | 2.01 Cr | 0.23 Cr | 2.04 Cr | 0.78 Cr | — |
| Total Expenses | 30.49 Cr | 28.66 Cr | 21.10 Cr | 23.54 Cr | — |
| Diluted NI Availto Com Stockholders | 2.01 Cr | 0.23 Cr | 2.04 Cr | 0.78 Cr | — |
| Net Income Common Stockholders | 2.01 Cr | 0.23 Cr | 2.04 Cr | 0.78 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 2.01 Cr | 0.23 Cr | 2.04 Cr | 0.78 Cr | — |
| Minority Interests | -53000.00 | — | — | — | — |
| Net Income Including Noncontrolling Interests | 2.01 Cr | 0.23 Cr | 2.04 Cr | 0.78 Cr | — |
| Net Income Discontinuous Operations | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income Continuous Operations | 2.01 Cr | 0.23 Cr | 2.04 Cr | 0.78 Cr | — |
| Tax Provision | 0.61 Cr | 0.37 Cr | 0.70 Cr | 0.27 Cr | — |
| Pretax Income | 2.62 Cr | 0.59 Cr | 2.74 Cr | 1.05 Cr | — |
| Other Non Operating Income Expenses | 45000.00 | — | 0.03 Cr | — | — |
| Special Income Charges | 0.00 | 0.00 | -0.17 Cr | 0.02 Cr | — |
| Net Non Operating Interest Income Expense | -0.31 Cr | -0.22 Cr | -0.03 Cr | -0.02 Cr | — |
| Interest Expense Non Operating | 0.31 Cr | 0.22 Cr | 0.06 Cr | 0.02 Cr | — |
| Operating Income | 2.92 Cr | 0.81 Cr | 2.94 Cr | 1.05 Cr | — |
| Operating Expense | 10.41 Cr | 8.68 Cr | 6.22 Cr | 6.08 Cr | — |
| Other Operating Expenses | 5.45 Cr | 3.52 Cr | 1.95 Cr | 2.84 Cr | — |
| Depreciation And Amortization In Income Statement | 0.10 Cr | 0.10 Cr | 0.13 Cr | 0.06 Cr | — |
| Depreciation Income Statement | 0.10 Cr | 0.09 Cr | 0.13 Cr | 0.06 Cr | — |
| Gross Profit | 13.34 Cr | 9.49 Cr | 9.17 Cr | 7.13 Cr | — |
| Cost Of Revenue | 20.08 Cr | 19.98 Cr | 14.88 Cr | 17.46 Cr | — |
| Total Revenue | 33.41 Cr | 29.47 Cr | 24.04 Cr | 24.59 Cr | — |
| Operating Revenue | 33.41 Cr | 29.47 Cr | 24.04 Cr | 24.59 Cr | — |
| Rent Expense Supplemental | — | 0.13 Cr | 0.13 Cr | 0.12 Cr | 0.12 Cr |
| Diluted Average Shares | — | 0.33 Cr | 0.43 Cr | 0.43 Cr | 0.43 Cr |
| Basic Average Shares | — | 0.33 Cr | 0.43 Cr | 0.43 Cr | 0.43 Cr |
| Diluted EPS | — | 0.68 | 4.76 | 1.81 | 0.39 |
| Basic EPS | — | 0.68 | 4.76 | 1.81 | 0.39 |
| Total Other Finance Cost | — | -10000.00 | -0.03 Cr | — | 4000.00 |
| Amortization | — | 26000.00 | 0.00 | — | — |
| Selling General And Administration | — | 1.09 Cr | 0.82 Cr | 0.52 Cr | 1.11 Cr |
| Selling And Marketing Expense | — | 0.55 Cr | 0.80 Cr | 0.50 Cr | 1.08 Cr |
| General And Administrative Expense | — | 0.54 Cr | 0.02 Cr | 0.03 Cr | 0.03 Cr |
| Rent And Landing Fees | — | 0.13 Cr | 0.13 Cr | 0.12 Cr | 0.12 Cr |
| Other Special Charges | — | — | 0.17 Cr | -0.02 Cr | — |
| Write Off | — | — | — | 0.00 | — |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Sunrest Lifescience Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.